| Dr Uche Patrick Maduka, MD | |
|
1550 Boyson Rd, Hiawatha, IA 52233-2362 | |
| (319) 743-7300 | |
| (319) 743-7311 |
| Full Name | Dr Uche Patrick Maduka |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 7 Years |
| Location | 1550 Boyson Rd, Hiawatha, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326575218 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | R-10865 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mercy Medical Center - Cedar Rapids | Cedar rapids, IA | Hospital |
| St Lukes Hospital | Cedar rapids, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Linn County Anesthesiologists Pc | 7911898283 | 45 |
News Archive
In the last several years, targeted therapies - drugs that directly impact specific genes and proteins involved in the progression of cancer - have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments.
In the first national report that compares the health and well-being of children with special health care needs to those children without, findings revealed that 14 to 19 percent of children in the United States have a special health care need, representing more than one in five households with children.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced the company has submitted a new drug application (NDA) for ARYMO ER (morphine sulfate) extended-release tablets for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
Cidara Therapeutics, Inc., a privately held biopharmaceutical company, announced today that it has completed a $32 million Series A financing that will enable it to advance candidates from the company's Cloudbreak™ targeted immunotherapy platform and biafungin™, a novel long acting echinocandin antifungal drug, into human clinical studies.
Grief in veterans of the wars in Afghanistan and Iraq has been as largely overlooked as post-traumatic stress disorder in the aftermath of the Vietnam War.
› Verified 5 days ago
| Entity Name | Linn County Anesthesiologists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386624328 PECOS PAC ID: 7911898283 Enrollment ID: O20040324000821 |
News Archive
In the last several years, targeted therapies - drugs that directly impact specific genes and proteins involved in the progression of cancer - have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments.
In the first national report that compares the health and well-being of children with special health care needs to those children without, findings revealed that 14 to 19 percent of children in the United States have a special health care need, representing more than one in five households with children.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced the company has submitted a new drug application (NDA) for ARYMO ER (morphine sulfate) extended-release tablets for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
Cidara Therapeutics, Inc., a privately held biopharmaceutical company, announced today that it has completed a $32 million Series A financing that will enable it to advance candidates from the company's Cloudbreak™ targeted immunotherapy platform and biafungin™, a novel long acting echinocandin antifungal drug, into human clinical studies.
Grief in veterans of the wars in Afghanistan and Iraq has been as largely overlooked as post-traumatic stress disorder in the aftermath of the Vietnam War.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Uche Patrick Maduka, MD 1550 Boyson Rd, Hiawatha, IA 52233-2362 Ph: (319) 743-7300 | Dr Uche Patrick Maduka, MD 1550 Boyson Rd, Hiawatha, IA 52233-2362 Ph: (319) 743-7300 |
News Archive
In the last several years, targeted therapies - drugs that directly impact specific genes and proteins involved in the progression of cancer - have been approved for a wide variety of cancers, including melanoma, the deadliest form of skin cancer. Now, researchers at The Wistar Institute have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, and understanding this phenomenon may lead to a new melanoma target or prompt new designs of these treatments.
In the first national report that compares the health and well-being of children with special health care needs to those children without, findings revealed that 14 to 19 percent of children in the United States have a special health care need, representing more than one in five households with children.
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and commercializing innovative treatments for pain and other conditions, announced the company has submitted a new drug application (NDA) for ARYMO ER (morphine sulfate) extended-release tablets for the management of pain severe enough to require daily, around-the-clock opioid treatment and for which alternative treatments are inadequate.
Cidara Therapeutics, Inc., a privately held biopharmaceutical company, announced today that it has completed a $32 million Series A financing that will enable it to advance candidates from the company's Cloudbreak™ targeted immunotherapy platform and biafungin™, a novel long acting echinocandin antifungal drug, into human clinical studies.
Grief in veterans of the wars in Afghanistan and Iraq has been as largely overlooked as post-traumatic stress disorder in the aftermath of the Vietnam War.
› Verified 5 days ago
Rimas J Nemickas, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1550 Boyson Rd, Hiawatha, IA 52233 Phone: 319-743-7300 Fax: 319-743-7311 | |
Muayyad Tailounie, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1550 Boyson Rd, Hiawatha, IA 52233 Phone: 319-743-7300 Fax: 319-743-7311 | |
Dr. Christina Sarrica, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1550 Boyson Rd, Hiawatha, IA 52233 Phone: 319-743-7300 | |
Kirsten Susan Leff, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1550 Boyson Rd, Hiawatha, IA 52233 Phone: 319-743-7300 Fax: 319-743-7311 | |
Ryan Tegtmeier, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 1550 Boyson Rd, Hiawatha, IA 52233 Phone: 319-743-7300 Fax: 319-743-7311 | |
Dr. Ginger Rose Massey, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1550 Boyson Rd, Hiawatha, IA 52233 Phone: 319-743-7300 Fax: 319-743-7311 |